Dream Experiences During Intensive Care Unit Stay: Occurrence, Content, Vividness and Associated Factors.

Background: Vivid dream experiences in the intensive care unit (ICU) are common, but poorly understood.

Aim: We investigated the occurrence, vividness, content, emotional impact and associated factors of dream experiences in the ICU.

Study Design: Retrospective mixed methods study with subjects ≥ 18 years, previously admitted to the ICU for ≥ 4 days and/or due to COVID-19, who were not sedated for ≥ 24 h during their stay (n = 80).

Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation.

Study Objectives: Central disorders of hypersomnolence (CDH) have a major impact on patients' quality of life (QoL). We developed and validated a disease-specific patient-reported outcome measure (PROM) to measure QoL in CDH: the PROM-CDH, for adults with narcolepsy types 1 and 2 (NT1 and NT2), and idiopathic hypersomnia (IH).

Methods: The developmental process involved focus groups and interviews with adults with CDH (n = 27), family members (n = 8) and sleep medicine specialists (n = 5).

Symptoms of central disorders of hypersomnolence during phases of female hormonal transitions: an explorative self-report study.

In clinical practice, women with central disorders of hypersomnolence (CDH) often report changes of symptom severity within their menstrual cycle and during menopausal transition. This explorative study among women with CDH investigates self-reported CDH symptom severity during these phases in a woman's life that are associated with female hormone transitions. N = 180 women with CDH (118 with narcolepsy type 1, 9 with narcolepsy type 2, 53 with idiopathic hypersomnia) filled out questions on CDH symptom changes within the menstrual cycle and/or during menopausal transition, if applicable to them.

Diagnostic value of nocturnal sleep-onset rapid eye movement sleep period for narcolepsy type 1 and 2 in a tertiary sleep centre.

Background: A nocturnal sleep-onset rapid eye movement period (nSOREMP) is considered diagnostic for narcolepsy type 1 (NT1) if typical cataplexy is also present. The diagnostic value of nSOREMP for narcolepsy type 2 (NT2) is less clear partly because it has not been studied in large groups representing the population attending a sleep centre. We examined the prevalence of nSOREMP and its diagnostic value for narcolepsy in clinical practice.